- Home
- BMRC vs ALDX Comparison
BMRC vs ALDX Comparison
Compare BMRC & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMRC
- ALDX
- Stock Information
- Founded
- BMRC 1989
- ALDX 2004
- Country
- BMRC United States
- ALDX United States
- Employees
- BMRC N/A
- ALDX N/A
- Industry
- BMRC Major Banks
- ALDX Biotechnology: Pharmaceutical Preparations
- Sector
- BMRC Finance
- ALDX Health Care
- Exchange
- BMRC Nasdaq
- ALDX Nasdaq
- Market Cap
- BMRC 384.1M
- ALDX 313.4M
- IPO Year
- BMRC N/A
- ALDX 2014
- Fundamental
- Price
- BMRC $22.71
- ALDX $5.26
- Analyst Decision
- BMRC Buy
- ALDX Strong Buy
- Analyst Count
- BMRC 4
- ALDX 2
- Target Price
- BMRC $26.25
- ALDX $9.50
- AVG Volume (30 Days)
- BMRC 67.1K
- ALDX 647.5K
- Earning Date
- BMRC 10-27-2025
- ALDX 11-06-2025
- Dividend Yield
- BMRC 4.40%
- ALDX N/A
- EPS Growth
- BMRC N/A
- ALDX N/A
- EPS
- BMRC 0.43
- ALDX N/A
- Revenue
- BMRC $93,409,000.00
- ALDX N/A
- Revenue This Year
- BMRC $61.22
- ALDX N/A
- Revenue Next Year
- BMRC $12.21
- ALDX $36.23
- P/E Ratio
- BMRC $52.53
- ALDX N/A
- Revenue Growth
- BMRC 59.35
- ALDX N/A
- 52 Week Low
- BMRC $19.14
- ALDX $1.14
- 52 Week High
- BMRC $27.11
- ALDX $7.20
- Technical
- Relative Strength Index (RSI)
- BMRC 38.81
- ALDX 48.59
- Support Level
- BMRC $22.50
- ALDX $5.13
- Resistance Level
- BMRC $24.42
- ALDX $5.79
- Average True Range (ATR)
- BMRC 0.62
- ALDX 0.28
- MACD
- BMRC -0.20
- ALDX -0.00
- Stochastic Oscillator
- BMRC 9.85
- ALDX 29.10
About BMRC Bank of Marin Bancorp
Bank of Marin Bancorp is a United States-based bank holding company. It conducts business through its wholly-owned subsidiary. The Bank provides a wide range of financial services to customers such as professionals, small and middle-market businesses, and individuals residing in Marin, Sonoma, Napa, San Francisco, Alameda, Contra Costa, San Mateo counties and others. The majority of its revenue comes from interest income.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.